Liquid biopsies, and particularly the analysis of circulating tumor DNA, are emerging as an interesting means for diagnosis, prognosis, and predictive biomarker discovery. We combined the amplification refractory mutation system (ARMS) with high-resolution melting analysis (HRMA) for detecting two of the most relevant KRAS mutations in codon 12. KRAS mutation screening was validated in tumor and plasma samples collected from patients with pancreatic ductal adenocarcinoma (PDAC) - Paper